Rankings
▼
Calendar
TGTX Q4 2025 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TGTX
TG Therapeutics, Inc.
$5B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$193M
+78.0% YoY
Gross Profit
$154M
80.2% margin
Operating Income
$50M
26.2% margin
Net Income
$23M
12.0% margin
EPS (Diluted)
$0.14
QoQ Revenue Growth
+19.1%
Cash Flow
Operating Cash Flow
$20M
Free Cash Flow
$20M
Stock-Based Comp.
$16M
Balance Sheet
Total Assets
$1.1B
Total Liabilities
$415M
Stockholders' Equity
$648M
Cash & Equivalents
$79M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$193M
$108M
+78.0%
Gross Profit
$154M
$93M
+66.4%
Operating Income
$50M
$30M
+68.6%
Net Income
$23M
$23M
-1.3%
Revenue Segments
Product
$189M
96%
Royalty
$5M
3%
Other Revenue
$3M
2%
← FY 2025
All Quarters